Cerevance announced the start of their Phase 1 trial, with the first participant dosed to evaluate the safety, tolerability, and pharmacokinetics of CVN293.

ImmPACT Bio USA, Inc has publicized that the initial patient has received treatment in the Phase 1/2 trial of IMPT-314.

MRM Health NV has announced encouraging preliminary outcomes from its Phase 2a clinical study of MH002 against mild-to-moderate Ulcerative Colitis.

Drug Farm, currently in the clinical phase, has shared the news of the first participant in the Phase 1 clinical experiment, testing DF-003, receiving their initial dosage.

The study on Atrial Fibrillation using Abelacimab was prematurely ended by the Data Monitoring Committee due to a massive decrease in bleeding compared to a DOAC.

LinKinVax and Gustave Roussy have reported that Gustave Roussy is treating the initial participant in a Phase I/IIa clinical trial using CD40HVac.

Artificial intelligence-focused Lantern Pharma Inc unveiled the FDA's approval of their IND application for LP-284.

Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc. announced EC's approval of INAQOVI® for treating newly diagnosed acute myeloid leukaemia in adults unfit for standard induction chemotherapy.

Atamyo Therapeutics made public its submission of a CTA for ATA-200 in European territories.

BeiGene, Ltd. revealed that TEVIMBRA®(tislelizumab) has received approval by the EC to be used as a single therapy for addressing unresectable.

ESSA Pharma Begins Phase 2 trial of Masofaniten (EPI-7386) in Combination with Enzalutamide for Patients Suffering from Metastatic Castration-Resistant Prostate Cancer.

FDA Prioritizes Review of Merck's Additional New Drug Submission for WELIREG® (belzutifan) for Previously Treated Patients with Advanced Renal Cell Carcinoma.